VYNE Therapeutics (NASDAQ:VYNE) Stock Price Down 1.4% – Here’s Why

VYNE Therapeutics Inc. (NASDAQ:VYNE) fell 1.4% on Friday . The stock traded as low as $0.6301 and last traded at $0.6561. 50,971 shares traded hands during mid-day trading, a decline of 64% from the average session volume of 142,873 shares. The stock had previously closed at $0.6651.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of VYNE Therapeutics in a report on Monday, May 4th. Three research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, VYNE Therapeutics has a consensus rating of “Reduce”.

VYNE Therapeutics Stock Performance

The business’s 50-day moving average is $0.64 and its two-hundred day moving average is $0.57. The firm has a market capitalization of $21.88 million, a price-to-earnings ratio of -1.73 and a beta of 2.00.

VYNE Therapeutics (NASDAQ:VYNE) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.10. The firm had revenue of $0.09 million during the quarter, compared to analysts’ expectations of $0.20 million. VYNE Therapeutics had a negative net margin of 4,726.21% and a negative return on equity of 70.42%. Analysts forecast that VYNE Therapeutics Inc. will post -1.1 EPS for the current year.

Institutional Trading of VYNE Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. XTX Topco Ltd acquired a new position in VYNE Therapeutics in the fourth quarter valued at about $46,000. Rangeley Capital LLC raised its position in shares of VYNE Therapeutics by 18.1% during the first quarter. Rangeley Capital LLC now owns 118,064 shares of the company’s stock worth $71,000 after purchasing an additional 18,064 shares during the period. Two Sigma Investments LP acquired a new stake in shares of VYNE Therapeutics during the third quarter worth about $74,000. Geode Capital Management LLC lifted its holdings in shares of VYNE Therapeutics by 64.2% during the 4th quarter. Geode Capital Management LLC now owns 225,152 shares of the company’s stock valued at $131,000 after purchasing an additional 88,030 shares in the last quarter. Finally, ADAR1 Capital Management LLC bought a new position in shares of VYNE Therapeutics during the 4th quarter valued at about $147,000. Institutional investors and hedge funds own 83.78% of the company’s stock.

VYNE Therapeutics Company Profile

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.